In the present study the possibility of the binding of the antitumor drug arglabin to human serum albumin (HSA) nanoparticles by adsorption was investigated. The particle size did not change after drug adsorption and was about 160 nm. Drug binding as well as the influence of arglabin on the physico-chemical characteristics of the nanoparticles was analysed. More than 60% of the initially added arglabin could be bound to the HSA nanoparticles at low drug concentrations.  At higher concentrations a plateau was reached with a minimum concentration of 39% of the added amount of arglabin yielding a loading of 13.5% compared to the HSA nanoparticle mass.